(Q37119330)

18 August 2017

1 reference

title

Management of arterial hypertension in obese patients (English)

1 reference

18 August 2017

arterial hypertension

0 references

obesity

0 references

author name string

Ulrich O Wenzel

series ordinal

1

1 reference

PubMed ID

18367013

18 August 2017

Christian Krebs

series ordinal

2

1 reference

18 August 2017

1 December 2007

1 reference

Current Hypertension Reports

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

491-497

1 reference

18 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-007-0090-7

18 August 2017

0 references

cites work

Cardiovascular regulation in obesity-induced hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0090-7

Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0090-7

Treatment of obesity hypertension and diabetes syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0090-7

Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0090-7

Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

21 January 2018

1 reference

12 December 2020

Pathophysiology and treatment of obesity hypertension

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Who cares about the obese hypertensive patient?

1 reference

12 December 2020

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

1 reference

12 December 2020

History about the discovery of the renin-angiotensin system

1 reference

12 December 2020

Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites

1 reference

12 December 2020

Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats.

1 reference

12 December 2020

Oral renin inhibitors

1 reference

12 December 2020

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes

1 reference

12 December 2020

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

1 reference

12 December 2020

The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study.

1 reference

12 December 2020

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group

1 reference

12 December 2020

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

1 reference

12 December 2020

Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled

1 reference

12 December 2020

Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension

1 reference

12 December 2020

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

Obesity: preventing and managing the global epidemic. Report of a WHO consultation

1 reference

12 December 2020

Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study

1 reference

12 December 2020

Use of aldosterone antagonists in resistant hypertension

1 reference

12 December 2020

Treatment of arterial hypertension in obese patients

1 reference

12 December 2020

Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries

1 reference

12 December 2020

European Society of Hypertension Working Group on Obesity: background, aims and perspectives.

1 reference

12 December 2020

Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension

1 reference

12 December 2020

Obesity as a determinant for response to antihypertensive treatment

1 reference

12 December 2020

Management of hypertension in overweight and obese patients: a practical guide for clinicians

1 reference

12 December 2020

Clinical management of the obese hypertensive patient

1 reference

12 December 2020

Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study

1 reference

12 December 2020

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

12 December 2020

Choice of drug treatment for obesity-related hypertension: where is the evidence?

1 reference

12 December 2020

Is there a rationale for angiotensin blockade in the management of obesity hypertension?

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies.

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review

1 reference

12 December 2020

Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension

1 reference

12 December 2020

Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population

1 reference

12 December 2020

Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension

1 reference

12 December 2020

The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology

1 reference

12 December 2020

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Direct renin inhibition with aliskiren in hypertension and target organ damage

1 reference

12 December 2020

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

12 December 2020

Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial

1 reference

12 December 2020

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

1 reference

12 December 2020

10.1007/S11906-007-0090-7

Identifiers

DOI

1 reference

release_bog2gv54anhc3cocv74ctnceu4

18 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bog2gv54anhc3cocv74ctnceu4

24 November 2022

mapped directly with Wikidata item

PubMed ID

18367013

1 reference

PubMed ID

18367013